花旗-恒瑞医药(1276.HK):花旗泛亚会议要点;HRS-1893(肌球蛋白)具备BIC潜力,今年启动全球三期临床试验-Takeaway from Citi’s Pan-Asia Conference;BIC Potential of HRS-1893(Myosin)starting Global Ph3 Trials This Year-20260520【13页】

发表回复

后才能评论